BCAX – bicara therapeutics inc. (US:NASDAQ)
Stock Stats
News
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
Bicara Therapeutics (NASDAQ:BCAX) had its price target raised by analysts at Wells Fargo & Company from $8.00 to $11.00. They now have an "equal weight" rating on the stock.
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Bicara Therapeutics GAAP EPS of -$0.67 [Seeking Alpha]
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Form EFFECT Bicara Therapeutics Inc.
Form 424B5 Bicara Therapeutics Inc.
Form 4 Bicara Therapeutics Inc. For: Nov 21 Filed by: Hyep Ivan
Form 4 Bicara Therapeutics Inc. For: Nov 21 Filed by: Cohlhepp Ryan
Form 4 Bicara Therapeutics Inc. For: Nov 24 Filed by: Mazumdar Claire
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.